1.A study of photodynamic therapy on experimental pancreatic cancer in a nude mouse model
Bo ZHANG ; Yupei ZHAO ; Taiping ZHANG
Chinese Journal of General Surgery 1994;0(05):-
ObjectiveTo investigate the therapeutic effect and the mechanism of photodynamic therapy (PDT) on human pancreatic cancer xenograft in nude mice.MethodsThe animal model of human pancreatic cancer was produced by injecting human pancreatic cancer cells SW1990 into the dorsum of nude mice. After photosensitizer hematoporphyrin derivatives(HpD) was injected, the 632.8?nm He Ne laser was used to irradiate the tumor. The tumor′s volume was measured and factor Ⅷ was used for the immunohistochemical staining of the vessel change.ResultsThe tumor growth rate significantly decreased after PDT. Immunohistochemical staining showed significant vessel endothelial cell injury by PDT.ConclusionsPDT has a therapeutic effect on grafted pancreatic cancer possibly by incurring vascular injury.
2.Improving prognosis of pancreatic cancer by standardization of surgical procedures and multimodality treatment
Taiping ZHANG ; Hanxiang ZHAN ; Yupei ZHAO
Chinese Journal of Hepatobiliary Surgery 2011;17(6):441-443
Pancreatic adenocarcinoma is a highly malignant tumor and its prognosis is poor. The key factors for cure and prolonged survival are early detection, adequate evaluation of resectability and surgical resection with microscopic tumor clearance. Surgeons should pay attention to standardize operative procedures to increase the R0 resection rate. Whipple specimens should be inked and examined carefully. Postoperative adjuvant radiotherapy and chemotherapy are beneficial in the prevention of local tumor recurrence and distant metastasis. Inter-disciplinary cooperation and multimodality treatment are helpful to improve the prognosis and quality of life of patients with pancreatic cancer.
3.Relationship between human equilibrative nucleoside transporter 1 and gemcitabine chemoresistance in pancreatic cancer
Jianchun XIAO ; Taiping ZHANG ; Yupei ZHAO
International Journal of Surgery 2012;39(10):698-701
Gemcitabine has become a first-line chemotherapeutic durg.Unfortunately,many patients fail to derive benefits from gemcitabine in clinics.The variability of human equilibrative nucleoside transporter 1 (hENT1)expression in tumor cells,which plays a dominant role in the transport of gemcitabine across the cell membrane,may be one of the reason for gemcitabine chemoresistance in pancreatic cancer.
4.Treatment strategies for patients with negative biopsy for pancreatic head mass
Taiping ZHANG ; Jian LI ; Yupei ZHAO
Chinese Journal of Hepatobiliary Surgery 2012;(11):809-812
The special anatomy around the head of pancreas leads to difficulties in arriving at a definitive diagnosis for a pancreatic head mass,the management of which has recently become a hot topic and a challenge for clinicians.Despite recent advances in tumor markers,ultrasound,CT,PET/CT and MRI,some of these pancreatic head masses cannot be diagnosed with certainty.A fine needle aspiration biopsy can be used before operation; however,false negative results not infrequently happen.Based on the reports from domestic and foreign medical literatures published recently,this paper reviewed and discussed the proper treatment strategies when biopsy results from a pancreatic head mass turn out negative.
5.MicroRNAs and solid tumors drug resistance
Jianwei XU ; Taiping ZHANG ; Yupei ZHAO
International Journal of Surgery 2011;38(3):182-185
Drug resistance is major obstacles in the successful treatment of malignant solid tumors. Multiple mechanisms involeve in development of cancer drug resistance. Recent research suggests dysregulation of microRNAs is associated with cancer drug resistance. The profiles of microRNAs in drug resistance cancer cells or tissues are different with sensitivity cells or tissues in various solid tumors. Restoring microRNAs could improve chemosensitivity of cancer cells. MicroRNAs expression profiles may provide a critical link for understanding mechanisms involved in chemoresistance. We can also find a specific marker for screening chemosensitivity patients through identification of the microRNAs patterns of drug resistance cells or tissues.
6.Clinical analysis of intraductal papillary mucinous neoplasm of pancreas in 27 cases
Junyang LU ; Taiping ZHANG ; Yupei ZHAO
International Journal of Surgery 2011;38(3):160-162
Objective To summarize the experience in diagnosis and treatment of intraductal papillary mucinous neoplasm(IPMN) of the pancreas and identify potential preoperative factors predicting invasiveness of intraductal papillary mucinous neoplasm of the pancreas. Methods From September 2003 to July 2010,27 patients underwent pancreatic resection for IPMN. All cases were divided into invasive and noninvasive groups. Preoperative medical records were reviewed retrospectively between the two groups. Results Pathological results revealed 15 cases of invasive IPMN and 12 noninvasive cases. The incidence of obstructive jaundice, tumor size and serum total bilirubin values were significantly different between the two groups. The other factors including sex ratio, age, incidence of abdominal pain or back pain, diarrhea, weight loss, new onset diabetes, serum CEA, CA19-9 values showed no statistical difference. Conclusion Serum total bilirubin≥22.2μmol/L and tumor size≥3 cm could be predicting factors of invasive IPMN.
7.Challenges and strategies in the diagnosis and treatment of pancreatic cancer
Taiping ZHANG ; Tianxiao WANG ; Yupei ZHAO
Chinese Journal of Digestive Surgery 2012;11(1):41-44
Pancreatic cancer is an aggressive malignant gastrointestinal tumor,surgical resection offers the only chance of cure. Due to its anatomic and biological characters,early stage pancreatic cancer is usually clinically silent,80%-85% of patients present with advanced unresectable disease. Furthermore,pancreatic cancer responds poorly to most radiochemotherapeutic agents.In this article,we discuss some clinical aspects including early diagnosis,preoperative systemic assessment,surgery and perioperartive adjuvant therapy,and we hope to find the challenges as well as strategies for pancreatic cancer in order to further improve the current level of diagnosis and treatment in China.
8.Progress in the diagnosis and treatment of pancreatic neuroendocrine tumors
Taiping ZHANG ; Guangbin XIONG ; Yupei ZHAO
Journal of Clinical Surgery 2015;(3):233-235
Pancreatic neuroendocrine tumors(pNETs)have a low prevalence,and may be func-tional as secreting biologically active substance or nonfunctional. With the increased understanding of this disease,new technologies are being developed for diagnosis and treatment. However,surgical excision re-mains the primary therapy for localized tumors and the cure rate is not ideal yet. In choosing the appropri-ate therapy for locally advanced/ metastatic pNETs,medical management strategy should be made in a multidisciplinary context. In addition to chemotherapy,there have been significant advances in targeted mo-lecular therapy.
9.Diagnosis and therapy of mesenteric fibromatosis:report of eleven cases
Xuequan FANG ; Taiping ZHANG ; Yupei ZHAO
International Journal of Surgery 2010;37(7):460-463
Objective To investigate the diagnosis and treatment of mesenteric fibromatosis.Methods We analyzed retrospectively the clinical data including clinical manifestation,treatment and follow-up results of the mesenteric fibromatosis in 11 cases.ResultsNine patients presented with abdominal mass.Two cases were found during other operation occasionally.Before operation,3 cases were misdiagnosed as leiomyosarcoma,1 case as malignant neurilemmoma,1 case as lymphoma.All patients were underwent surgical resection,and were diagnosed as mesenteric fibromatosis by pathology.Following-up,from 7 months to 72 months,2 cases relapsed.Conclusions The clinical feature of mesenteric fibromatosis is nonspecific.It is difficult to make correct diagnosis preoperatively.Surgical resection is the first choice for cure of patients with mesenteric fibromatosis.
10.How to improve the early diagnosis of pancreatic cancer
Taiping ZHANG ; Hanxiang ZHAN ; Yupei ZHAO
Chinese Journal of Digestive Surgery 2009;8(4):251-253
Pancreatic cancer is highly malignant with a poor prognosis. The resectability and prognosis of early pancreatic cancer are much better than the advanced, so early diagnosis is crucial for saving patients' lives. Because the symptoms of pancreatic cancer are non-specific, most of the patients are misdiagnosed as gastrointestinal or hepatobiliary diseases. Early diagnosis rate of pancreatic cancer can be greatly improved by combined application of tumor marker detection, endoscopic ultrasound, computed tomography, positron emission tomo-graphy, and etc. Early screening of high-risk population has been advocated by the experts, and its value in early diagnosis of pancreatic cancer has been confirmed by relevant studies. The colaboration of multiple pancreatic surgery centers in conducting prospective studies and setting gnidlines for the pancreatic cancer diagnosis, and relevant fundamental reseaches should also be emphasized.